196 related articles for article (PubMed ID: 25071006)
21. FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Lu C; Cui C; Liu B; Zou S; Song H; Tian H; Zhao J; Li Y
Neurosci Lett; 2017 Sep; 657():77-83. PubMed ID: 28778805
[TBL] [Abstract][Full Text] [Related]
22. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
[TBL] [Abstract][Full Text] [Related]
23. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Séry Q; Rabé M; Oliver L; Vallette FM; Gratas C
Biochem Biophys Res Commun; 2017 Dec; 493(4):1377-1383. PubMed ID: 28970067
[TBL] [Abstract][Full Text] [Related]
24. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
[TBL] [Abstract][Full Text] [Related]
25. The carboxyl terminus of FANCE recruits FANCD2 to the Fanconi Anemia (FA) E3 ligase complex to promote the FA DNA repair pathway.
Polito D; Cukras S; Wang X; Spence P; Moreau L; D'Andrea AD; Kee Y
J Biol Chem; 2014 Mar; 289(10):7003-7010. PubMed ID: 24451376
[TBL] [Abstract][Full Text] [Related]
26. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
27. LncRNA-XIST interacts with
Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
[TBL] [Abstract][Full Text] [Related]
28. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Flüh C; Chitadze G; Adamski V; Hattermann K; Synowitz M; Kabelitz D; Held-Feindt J
Histochem Cell Biol; 2018 Mar; 149(3):219-233. PubMed ID: 29356965
[TBL] [Abstract][Full Text] [Related]
29. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
30. A novel role for Fanconi anemia (FA) pathway effector protein FANCD2 in cell cycle progression of untransformed primary human cells.
Song IY; Barkley LR; Day TA; Weiss RS; Vaziri C
Cell Cycle; 2010 Jun; 9(12):2375-88. PubMed ID: 20519958
[TBL] [Abstract][Full Text] [Related]
31. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
[TBL] [Abstract][Full Text] [Related]
32. Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Lin L; Wang G; Ming J; Meng X; Han B; Sun B; Cai J; Jiang C
Tumour Biol; 2016 Nov; 37(11):15333-15339. PubMed ID: 27704357
[TBL] [Abstract][Full Text] [Related]
33. [Molecular pharmacology on DNA methylating agent temozolomide].
Hirose Y; Sano H
No Shinkei Geka; 2007 Feb; 35(2):117-29. PubMed ID: 17310751
[No Abstract] [Full Text] [Related]
34. Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Shiraki Y; Mii S; Enomoto A; Momota H; Han YP; Kato T; Ushida K; Kato A; Asai N; Murakumo Y; Aoki K; Suzuki H; Ohka F; Wakabayashi T; Todo T; Ogawa S; Natsume A; Takahashi M
J Pathol; 2017 Dec; 243(4):468-480. PubMed ID: 28888050
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Ramirez YP; Mladek AC; Phillips RM; Gynther M; Rautio J; Ross AH; Wheelhouse RT; Sakaria JN
Mol Cancer Ther; 2015 Jan; 14(1):111-9. PubMed ID: 25351918
[TBL] [Abstract][Full Text] [Related]
36. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Maxwell JA; Johnson SP; McLendon RE; Lister DW; Horne KS; Rasheed A; Quinn JA; Ali-Osman F; Friedman AH; Modrich PL; Bigner DD; Friedman HS
Clin Cancer Res; 2008 Aug; 14(15):4859-68. PubMed ID: 18676759
[TBL] [Abstract][Full Text] [Related]
37. FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway.
Gordon SM; Alon N; Buchwald M
J Biol Chem; 2005 Oct; 280(43):36118-25. PubMed ID: 16127171
[TBL] [Abstract][Full Text] [Related]
38. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Hayashi T; Adachi K; Ohba S; Hirose Y
J Neurooncol; 2013 Nov; 115(2):169-78. PubMed ID: 23943501
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Bruyère C; Mijatovic T; Lonez C; Spiegl-Kreinecker S; Berger W; Kast RE; Ruysschaert JM; Kiss R; Lefranc F
Int J Oncol; 2011 May; 38(5):1453-64. PubMed ID: 21399866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]